Pfizer (PFE) Navigates Patent Losses With Strategic Cost Controls, BMO Capital Reaffirms Outperform Rating

Core Viewpoint - Pfizer Inc. is considered one of the best stocks under $25 to buy now, despite a cautious outlook for 2026, with BMO Capital reaffirming an Outperform rating and a $30 price target [1]. Financial Projections - Pfizer anticipates adjusted profit to be between $2.80 and $3 per share for the upcoming year [1]. - The company's revenue is expected to be flat, ranging from $59.5 billion to $62.5 billion, compared to the updated 2025 sales forecast of $62 billion [1]. - A year-over-year reduction in sales of $1.5 billion is forecasted due to certain medications losing market exclusivity [2]. Market Dynamics - Pfizer's pneumonia vaccination Prevnar is facing increased competition, impacting sales [2]. - The softer 2026 projection is primarily driven by uncertainty in the Covid business, which is expected to decline by 23% year-over-year to around $5 billion in total revenue [2]. Strategic Initiatives - Future discussions are expected to focus on Pfizer's recent acquisition of Metsera and ongoing cost-saving efforts, which have already surpassed 2025 projections [3]. - Pfizer operates as a global biopharmaceutical company, focusing on wellness, prevention, treatment, and cures in both developing and emerging markets [3].